Core Viewpoint - The animal vaccine sector has shown a significant increase, with a 4.00% rise, ranking third among concept sectors, driven by notable gains in several stocks [1][2]. Group 1: Sector Performance - As of May 20, the animal vaccine concept increased by 4.00%, with 19 stocks rising, including *ST Xianfeng, which hit the daily limit, and others like Kexing Pharmaceutical, Ruipu Biological, and Kanghua Biological, which rose by 15.56%, 8.41%, and 6.70% respectively [1][2]. - The animal vaccine sector was among the top-performing sectors, alongside cultivated diamonds and pet economy, which rose by 4.10% and 4.08% respectively [2]. Group 2: Capital Inflow - The animal vaccine sector saw a net inflow of 67 million yuan, with 13 stocks receiving net inflows, and 6 stocks attracting over 10 million yuan in net inflows [2]. - Jinhe Biological led the net inflow with 36.88 million yuan, followed by Kexing Pharmaceutical, Dabeinong, and Plk, which received net inflows of 15.38 million yuan, 13.79 million yuan, and 13.60 million yuan respectively [2][3]. Group 3: Capital Flow Ratios - Stocks such as *ST Xianfeng, Kexing Pharmaceutical, and KQ Biotech had the highest net inflow ratios, at 14.17%, 6.56%, and 5.52% respectively [3]. - The top stocks in terms of capital inflow included Jinhe Biological with a turnover rate of 18.22% and a daily increase of 4.40%, and Kexing Pharmaceutical with a turnover rate of 3.46% and a daily increase of 15.56% [3][4].

Core Viewpoint - The article summarizes significant announcements from various listed companies in the Shanghai and Shenzhen stock markets, providing insights for investors on recent corporate actions and developments. Group 1: Corporate Announcements - Kweichow Moutai's shareholders approved a profit distribution plan for 2024, proposing a cash dividend of 276.24 yuan per 10 shares, totaling 34.672 billion yuan [3] - Weir Shares plans to change its name to "Haowei Group" and its stock abbreviation to "Haowei Group," pending shareholder approval [4] - Weili intends to transfer 100% equity of its subsidiary Dunhua Zhongneng to Chengfa Environment for a total consideration of approximately 323 million yuan [6] - Wanrun New Energy signed a business cooperation agreement with CATL to supply lithium iron phosphate products, with an estimated total supply of about 1.3231 million tons from 2025 to 2030 [7] - Shouhua Gas plans to purchase bauxite resources through market means, with a financing application of up to 2 billion yuan [8] Group 2: Regulatory and Compliance - Gao Neng Environment received an administrative regulatory decision from the Beijing Securities Regulatory Bureau due to insufficient impairment testing and inaccurate disclosures [9] - ST Shilong applied to revoke its other risk warning status, indicating compliance with relevant regulations [14] Group 3: Mergers and Acquisitions - Huixin Electronics plans to acquire 67.91% of Baode Computer through a combination of cash and stock issuance, enhancing its position in the IT infrastructure sector [19] - Kangping Technology intends to acquire 100% of Sulu Electronics for 198 million yuan to expand its electric tools business [23] - Xinjiang Haoyuan plans to change its name to "Wanqing Energy" to better reflect its business structure [26] Group 4: Financing and Investments - Shanghai Xinyang plans to invest 30 million yuan in the establishment of the Qixin Fund, focusing on high-tech sectors [12] - Taihe Co. intends to invest up to 150 million USD (approximately 1.082 billion yuan) in a pesticide and functional chemicals project in Egypt [28] Group 5: Strategic Partnerships and Contracts - Dongzhu Ecology signed a 3.5 billion yuan EPC contract for land consolidation in Laos [30] - Youa Co. signed a strategic cooperation framework agreement with Changsha Guokong Capital and Tsinghua Electronics Institute to promote the semiconductor industry [32] Group 6: Shareholder Actions - Wanfeng Co. plans to reduce its stake by up to 1.75% through block trading [35] - Tuoershi's controlling shareholder intends to reduce its stake by up to 2% [36]

证券代码：688526 证券简称：科前生物 公告编号：2025-026 武汉科前生物股份有限公司 第四届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、监事会会议召开情况 武汉科前生物股份有限公司（下称"公司"）于 2025 年 5 月 19 日以现场和通讯相结合的形式召开第四届监事会第九次会议（下称 "本次会议"）。本次会议通知于 2025 年 5 月 14 日以邮件、电话的 方式向各位监事发出，本次会议由监事会主席吴斌先生主持，本次会 议应参与表决监事 3 人，实际参与表决监事 3 人。本次会议的召集、 召开程序均符合《公司法》、《证券法》等法律、法规和规范性文件 以及《公司章程》的规定。 二、监事会会议审议情况 经与会监事审议，作出决议如下： (一）审议通过《关于公司与华中农大签订合作研发协议暨关联 交易的议案》 监事会认为：公司本次签订合作研发协议暨关联交易符合公司整 体发展方向，本次关联交易的审批程序合法合规，不存在损害公司及 股东利益的情形。 具体内容详见公司于同日刊登在上海证券 ...

证券代码：688526 证券简称：科前生物 公告编号：2025-025 武汉科前生物股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 5 月 19 日 （二） 股东会召开的地点：湖北武汉东湖新技术开发区高新二路 419 号科前生 物二楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 57 | | --- | --- | | 普通股股东人数 | 57 | | 2、出席会议的股东所持有的表决权数量 | 343,728,273 | | 普通股股东所持有表决权数量 | 343,728,273 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 74.0927 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 74.0927 | 注 ...

根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上 海证券交易所科创板股票上市规则》等有关法律、法规和规范性文件 以及《武汉科前生物股份有限公司章程》（下称"《公司章程》"） 等有关规定。我们作为武汉科前生物股份有限公司（以下简称"公司"） 的独立董事，基于独立判断的立场，本着对公司、全体股东负责的态 度，秉持实事求是的原则，对公司第四届董事会第十次会议审议的《关 于公司拟与华中农大签订合作研发协议暨关联交易的议案》进行了认 真调查和核查，并发表独立意见如下： 公司本次拟与华中农大签订合作研发协议，有利于提高公司在生 物制品领域的核心竞争力，加快公司在生物制品行业的发展，并且履 行了《公司章程》、《合作研发管理制度》以及《华中农业大学与武汉 科前生物股份有限公司之合作研发框架协议》规定的程序。本次交易 构成关联交易，本次关联交易表决程序合法，交易价格公允，上述交 易不存在损害公司、全体股东的情形。我们一致同意本次公司与华中 农大签订合作研发协议事项。 独立董事：罗飞 王宏林 王晖 2025 年 5 月 19 日 武汉科前生物股份有限公司 独立董事关于第四届董事会第十次会议 相关事项的独立意见 ...

重要内容提示： 关联交易简要内容：武汉科前生物股份有限公司（下称"科 前生物"或"公司"）经与华中农业大学（下称"华中农大"）竞争 性谈判，取得了"猪传染性胸膜肺炎-链球菌病-巴氏杆菌病"三联灭 活疫苗、"猪圆环病毒病、革拉瑟氏病、链球菌病、支原体肺炎"四 联亚单位疫苗两个项目的合作研发，现拟与华中农大签订联合开发协 议书，公司就以上两个研发项目一共需向华中农大支付 400 万元人民 币。合作研发项目产生的技术成果及知识产权归公司及华中农大共同 所有； 本次交易构成关联交易，不构成《上市公司重大资产重组管 理办法》规定的重大资产重组； 证券代码：688526 证券简称：科前生物 公告编号：2025-027 武汉科前生物股份有限公司 关于拟与华中农大签订合作研发协议暨关联交易的 自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 本次关联交易实施不存在重大法律障碍； 本次关联交易已经公司第四届董事会独立董事 2025 年第三次 会议、第四届董事会第十次会议及第四届监事会第九次会议审议通过， 本事项无需提交股东大 ...

北京市嘉源律师事务所 关于武汉科前生物股份有限公司 2024 年年度股东会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 二〇二五年五月 致:武汉科前生物股份有限公司 北京市嘉源律师事务所 关于武汉科前生物股份有限公司 2024 年年度股东会的 法律意见书 -11 科前生物 2024年年度股东会 法律意见书 原管师事务所 A YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN·香港 HONGKONG· 广州 GUANGZHOU·西安 XI'AN 股份有限公司 2024年年度股东大会会议材料》。 4. 本次股东会采取现场投票与网络投票相结合的方式进行。 5. 本次股东会现场会议于 2025年 5 月 19 日下午 14:00 在湖北武汉东湖新 技术开发区高新二路 419 号科前生物二楼会议室召开,现场会议由公司董事长陈 慕琳女士主持。本次股东会的网络投票通过上海证券交易所股东大会网络投票系 统(以下简称"网络投票系统")进行,股东既可以登陆交易系统投票平台进行投 票,也可以登陆互联网投票平台进行投票。股东通过交易系统投票平台 ...

证券代码：688526 证券简称：科前生物 公告编号：2025-026 武汉科前生物股份有限公司 第四届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 (一）审议通过《关于公司与华中农大签订合作研发协议暨关联 交易的议案》 监事会认为：公司本次签订合作研发协议暨关联交易符合公司整 一、监事会会议召开情况 武汉科前生物股份有限公司（下称"公司"）于 2025 年 5 月 19 日以现场和通讯相结合的形式召开第四届监事会第九次会议（下称 "本次会议"）。本次会议通知于 2025 年 5 月 14 日以邮件、电话的 方式向各位监事发出，本次会议由监事会主席吴斌先生主持，本次会 议应参与表决监事 3 人，实际参与表决监事 3 人。本次会议的召集、 召开程序均符合《公司法》、《证券法》等法律、法规和规范性文件 以及《公司章程》的规定。 二、监事会会议审议情况 经与会监事审议，作出决议如下： 体发展方向，本次关联交易的审批程序合法合规，不存在损害公司及 股东利益的情形。 具 体 内 容 详 见 公 司 于 ...

Investment Rating - The report maintains a "Positive" outlook on the Agriculture, Forestry, Animal Husbandry, and Fishery industry [2] Core Insights - The overall revenue of the industry remains stable, with significant improvement in the profitability of the breeding chain. In 2024, the SW Agriculture, Forestry, Animal Husbandry, and Fishery industry achieved total operating revenue of CNY 12,411.05 billion, a year-on-year decline of 1.67%. The net profit attributable to shareholders was CNY 479.85 billion, marking a turnaround from losses in 2023. In Q1 2025, the industry achieved total operating revenue of CNY 2,907.39 billion, a year-on-year increase of 8.09%, with net profit attributable to shareholders reaching CNY 133.35 billion, a significant increase compared to the same period last year [4][17][22]. Summary by Sections 1. Agriculture, Forestry, Animal Husbandry, and Fishery Industry - The industry shows overall stable revenue with a significant improvement in profitability. The operating revenue for 2024 was CNY 12,411.05 billion, down 1.67% year-on-year, while the net profit was CNY 479.85 billion, indicating a recovery from losses in 2023. In Q1 2025, the revenue increased by 8.09% year-on-year to CNY 2,907.39 billion, with net profit rising significantly [4][17][22]. 2. Swine Industry - The profitability of the swine industry has improved significantly, with major companies like Muyuan Foods, Wens Foodstuff Group, and New Hope Liuhe reporting revenue growth of 24.43%, 16.64%, and -27.27% respectively in 2024. The net profit for these companies increased by 519.42%, 244.46%, and 90.50% respectively. In Q1 2025, the top five swine companies saw substantial net profit growth, with Shen Nong Group leading at 6510.85% [30][45]. 3. Animal Health - The animal health sector faced significant pressure, with many companies experiencing revenue declines in 2024. However, Q1 2025 showed signs of recovery, particularly in the chemical drug segment, driven by a rebound in prices of veterinary raw materials. The top three companies in revenue growth for Q1 2025 were Huisheng Biological, Jinhai Biological, and Ruipu Biological, with increases of 20.42%, 7.58%, and 5.97% respectively [49][50]. 4. Feed Industry - The feed industry experienced a decline in total production in 2024, with a 2.10% drop year-on-year. However, revenue began to recover in Q1 2025, with leading companies like Bangji Technology and Haida Group showing significant growth. The average gross profit per ton for major feed companies also improved, with Haida Group achieving a gross profit margin of 12.66% in Q1 2025 [62][65][68]. 5. Poultry Industry - The poultry sector showed varied performance across different categories. In 2024, the top three companies in revenue growth were Xiaoming Co., Lihua Co., and Xiangjia Co., with increases of 16.83%, 15.44%, and 8.06% respectively. The profitability of the poultry industry improved significantly, with Lihua Co. leading in net profit growth at 447.72% [76][78].

Group 1 - The A-share market saw a collective decline on May 16, while the Sci-Tech Innovation Pharmaceutical sector rebounded, with the Sci-Tech Innovation Pharmaceutical ETF (588860) rising by 0.16% [1] - Notable stocks in the sector included Maiwei Biotech-U, which increased by over 5%, along with Shouyao Holdings-U, KQ Biotech, Innotec, CanSino, and Baotai, all of which experienced gains [1] - The Sci-Tech Innovation Pharmaceutical ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which selects 50 large-cap companies in biopharmaceuticals and related fields to reflect the overall performance of representative companies in the sector [1] Group 2 - According to CMB International, the optimization of centralized procurement policies in mainland China provides hospitals and enterprises with more flexibility and autonomy, benefiting leading prescription drug companies [2] - The anticipated implementation of favorable policies, such as the 2025H2 medical insurance category, is expected to accelerate industry consolidation, with the sector's valuations remaining at historical lows [2] - The recommendation is to focus on innovative drug targets with high growth potential or clear breakeven timelines after short-term sentiment stabilizes [2]